NovImmune SA-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:NovImmune SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013969
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NovImmune SA (NovImmune) is a biopharmaceutical company that discovers and develops antibody-based drugs for the treatment of inflammatory diseases, immune-related disorders and cancer. The company develops pipeline products using its proprietary mAb generating platform, DiversityTrap and kappa-lambda bispecific antibody platform. Its pipeline products include Emapalumab, a human anti-IFN? monoclonal antibody used for the treatment of Hemophagocytic Lymphohistiocytosis; NI-0101, a toll-like receptor 4 monoclonal antibody; NI-1201, a monoclonal antibody intended to interact with IL-6 receptor to suppress Interleukin-6 (IL-6) driven inflammation; and others. The company has partnership with various pharmaceutical companies, to develop monoclonal and bispecific antibodies. It has a presence in Geneva and Basel, Switzerland. NovImmune is headquartered in Geneva, Switzerland.

NovImmune SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
NovImmune SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
NovImmune SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
NovImmune SA, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
NovImmune Raises USD31 Million in Financing Round 10
Novimmune Raises USD30 Million in Venture Financing 11
NovImmune Raises Additional US$67.3 Million In Series B Financing 12
Partnerships 13
Novimmune and LegoChem Biosciences Enter into Research Agreement 13
Novimmune Enters into Research Agreement with Baxalta 14
Algenics Enters Into Research Collaboration With NovImmune 15
Licensing Agreements 16
Shire Enters into Licensing Agreement with Novimmune 16
Tiziana Life Sciences Enters into Licensing Agreement with Novimmune 17
Genentech Enters into Licensing Agreement with Novimmune 18
Tiziana Life Sciences Enters into Licensing Agreement with Novimmune for Foralumab 19
NovImmune SA – Key Competitors 20
NovImmune SA – Key Employees 21
NovImmune SA – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Corporate Communications 23
Nov 28, 2016: Novimmune appoints Global Head of Project Management 23
Sep 19, 2016: Novimmune broadens Senior Management Team — appointing Chief Financial Officer and Global Head of Quality 24
Product News 25
03/27/2017: Novimmune opens a Branch Office in Basel 25
Product Approvals 26
Jun 06, 2016: Novimmune lead program, NI-0501, granted eligibility for PRIME scheme in Europe 26
Mar 16, 2016: Novimmune’s NI-0501 Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients With Primary Hemophagocytic Lymphohistiocytosis 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
NovImmune SA, Pharmaceuticals & Healthcare, Key Facts 2
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
NovImmune SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
NovImmune SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
NovImmune SA, Deals By Therapy Area, 2011 to YTD 2017 8
NovImmune SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
NovImmune Raises USD31 Million in Financing Round 10
Novimmune Raises USD30 Million in Venture Financing 11
NovImmune Raises Additional US$67.3 Million In Series B Financing 12
Novimmune and LegoChem Biosciences Enter into Research Agreement 13
Novimmune Enters into Research Agreement with Baxalta 14
Algenics Enters Into Research Collaboration With NovImmune 15
Shire Enters into Licensing Agreement with Novimmune 16
Tiziana Life Sciences Enters into Licensing Agreement with Novimmune 17
Genentech Enters into Licensing Agreement with Novimmune 18
Tiziana Life Sciences Enters into Licensing Agreement with Novimmune for Foralumab 19
NovImmune SA, Key Competitors 20
NovImmune SA, Key Employees 21
NovImmune SA, Other Locations 22

★海外企業調査レポート[NovImmune SA-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • LGC Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary LGC Ltd (LGC), formerly LGC (Teddington) Ltd is a life sciences measurement and testing company that offers reference materials, genomics solutions and analytical testing products and services. The company’s products comprise DNA extraction instrumentation, DNA extraction kits, Douglas scien …
  • Consumers Energy Co (CMS PR B):電力:M&Aディール及び事業提携情報
    Summary Consumers Energy Co (Consumers), formerly Consumers Power, is an electric and natural gas utility. The company generates purchases, transmits, distributes, and sells electricity. It also carries out the purchase, transmission, storage, distribution, and sale of natural gas. It generates elec …
  • Kazakhtelecom (KZTK):企業の財務・戦略的SWOT分析
    Kazakhtelecom (KZTK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Catalyst Biosciences Inc (CBIO):企業の財務・戦略的SWOT分析
    Summary Catalyst Biosciences Inc (Catalyst Biosciences), formerly Targacept Inc, is a clinical-stage biopharmaceutical company that develops protease-based advanced medicines to treat hematological indications. The company specializes in hemostasis, with focus on subcutaneous prophylaxis of hemophil …
  • Sysco Corporation:企業の戦略・SWOT・財務分析
    Sysco Corporation - Strategy, SWOT and Corporate Finance Report Summary Sysco Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Groupe Lactalis S.A.:企業のM&A・事業提携・投資動向
    Groupe Lactalis S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Groupe Lactalis S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Yes Bank Ltd:企業の戦略・SWOT・財務分析
    Yes Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Yes Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Exelon Generation Company LLC:発電所・企業SWOT分析
    Exelon Generation Company LLC - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Petra Diamonds Ltd:企業の戦略・SWOT・財務情報
    Petra Diamonds Ltd - Strategy, SWOT and Corporate Finance Report Summary Petra Diamonds Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • SeaWorld Entertainment, Inc.:企業の戦略・SWOT・財務情報
    SeaWorld Entertainment, Inc. - Strategy, SWOT and Corporate Finance Report Summary SeaWorld Entertainment, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Terex Corp:企業の戦略・SWOT・財務分析
    Terex Corp - Strategy, SWOT and Corporate Finance Report Summary Terex Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Mount Tam Biotechnologies Inc (MNTM):企業の財務・戦略的SWOT分析
    Summary Mount Tam Biotechnologies Inc (Mount Tam Biotechnologies), a subsidiary of TabacaleraYsidron Inc is a provider of pharmaceutical products that offers development and commercialization of medical compounds for autoimmune diseases. The company’s lead product candidate TAM-0, a rapamycin analog …
  • Pliant Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pliant Therapeutics Inc (Pliant Therapeutics) is a biotechnology company that strives to discover, develop and commercialize treatments for fibrotic diseases. The company harnesses its capabilities in integrin biology, medicinal chemistry, clinical insight and TGF-ß modulation to block or re …
  • Polski Koncern Naftowy Orlen SA (PKN):石油・ガス:M&Aディール及び事業提携情報
    Summary Polski Koncern Naftowy Orlen SA (PKN Orlen) is an integrated oil and gas company. It explores for and produces crude oil and natural gas; manufactures petroleum products; transports and sells crude oil and petroleum products; and markets natural gas and natural gas liquids. Its product portf …
  • Airports of Thailand Plc (AOT):企業の財務・戦略的SWOT分析
    Airports of Thailand Plc (AOT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Synthomer plc (SYNT):企業の財務・戦略的SWOT分析
    Synthomer plc (SYNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • YTL Power International Berhad (YTLPOWR)-エネルギー分野:企業M&A・提携分析
    Summary YTL Power International Berhad (YTL Power), a subsidiary of YTL Corporation Berhad is an investment holding company which is active in the fields of power generation, transmission and supply; water supply and wastewater services; and telecommunications. It undertakes it power generation, tra …
  • PDC Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    PDC Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary PDC Energy Inc (PDC Energy) is an oil and gas company that offers production, development, exploration and marketing of crude oil, natural gas and natural gas liquids. The company provides horizontal …
  • Regenicin Inc (RGIN):製薬・医療:M&Aディール及び事業提携情報
    Summary Regenicin Inc (Regenicin), formerly Windstar Inc is a biotechnology company that develops regenerative cell therapies. The company offers NovaDerm, a tissue-engineered skin prepared from autologous skin cells. Its NovaDerm technology uses the patient’s own skin cells to generate living, tiss …
  • Dare Bioscience Inc (DARE):製薬・医療:M&Aディール及び事業提携情報
    Summary Dare Bioscience Inc (Dare Bioscience), formerly Cerulean Pharma Inc, is a clinical stage biopharmaceutical company that develops products for women’s reproductive health. The company, through its dynamic tumor targeting platform, creates nanoparticle drug conjugates to attack tumor cells, re …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆